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Transgenic expression of oncogenic BRAF induces loss of stem
cells in the mouse intestine, which is antagonized by β-catenin
activity
P Riemer1,2, A Sreekumar1,2, S Reinke2, R Rad3,4, R Schäfer1,4, C Sers1,4, H Bläker5, BG Herrmann2 and M Morkel1,2
Colon cancer cells frequently carry mutations that activate the β-catenin and mitogen-activated protein kinase (MAPK) signaling
cascades. Yet how oncogenic alterations interact to control cellular hierarchies during tumor initiation and progression is largely
unknown. We found that oncogenic BRAF modulates gene expression associated with cell differentiation in colon cancer cells. We
therefore engineered a mouse with an inducible oncogenic BRAF transgene, and analyzed BRAF effects on cellular hierarchies in
the intestinal epithelium in vivo and in primary organotypic culture. We demonstrate that transgenic expression of oncogenic BRAF
in the mouse strongly activated MAPK signal transduction, resulted in the rapid development of generalized serrated dysplasia, but
unexpectedly also induced depletion of the intestinal stem cell (ISC) pool. Histological and gene expression analyses indicate that
ISCs collectively converted to short-lived progenitor cells after BRAF activation. As Wnt/β-catenin signals encourage ISC identity, we
asked whether β-catenin activity could counteract oncogenic BRAF. Indeed, we found that intestinal organoids could be partially
protected from deleterious oncogenic BRAF effects by Wnt3a or by small-molecule inhibition of GSK3β. Similarly, transgenic
expression of stabilized β-catenin in addition to oncogenic BRAF partially prevented loss of stem cells in the mouse intestine. We
also used BRAFV637E knock-in mice to follow changes in the stem cell pool during serrated tumor progression and found ISC marker
expression reduced in serrated hyperplasia forming after BRAF activation, but intensiﬁed in progressive dysplastic foci characterized
by additional mutations that activate the Wnt/β-catenin pathway. Our study suggests that oncogenic alterations activating the
MAPK and Wnt/β-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon
cancer initiation and progression. Notably, loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel
fail-safe mechanism protecting intestinal tissue from oncogene activation.
Oncogene advance online publication, 11 August 2014; doi:10.1038/onc.2014.247
INTRODUCTION
The colon is lined by a single-layered epithelium folded into
functional domains termed crypts, while the small intestine in
addition contains villi that protrude into the intestinal lumen. The
resulting tissue structure is highly ordered and contains a basal
compartment with intestinal stem cells (ISCs) giving rise to
transiently amplifying (TA) progenitor cells. These in turn
differentiate into enterocytes and secretory cell types.1 Cellular
hierarchies are gradually modiﬁed during intestinal tumor
initiation and progression by mutations in signaling pathways
controlling homeostasis. Consequently, colon cancers can there-
fore exhibit gene activity characteristic for different intestinal cell
types and colon cancer subtypes deﬁned by such expression
patterns differ in their therapeutic response.2 It is largely unknown
which oncogenic mutations modulate differentiation patterns
during colon cancer progression and which constraints exist in the
tumor to balance stem cell traits, proliferation and differentiation.
Colon cancer can form via different pathways, with conven-
tional adenomas representing the most frequent benign precursor
lesions. These initiate mainly, if not exclusively, via mutations
activating the Wnt/APC/β-catenin signaling pathway in humans3
and in the mouse.4,5 In the normal intestine, Wnt signals are
emitted in the crypt base by secretory Paneth cells and
myoﬁbroblasts and received by ISCs and in an autocrine manner
by Paneth cells.1 Wnt signals inactivate the kinase GSK3β, resulting
in stabilization of β-catenin and transcription of β-catenin/TCF4
target genes.6 Wnt/β-catenin signals in the crypt are required for
ISC maintenance. In line, loss of intestinal Wnt/β-catenin signals by
genetic ablation of the transcription factor TCF4 results in loss of
the stem cell compartment and ultimately in loss of the intestinal
epithelium in the mouse.7,8 In contrast, activation of β-catenin is
sufﬁcient to modulate intestinal cellular hierarchies toward
adenomatous stem cell fates.9
Sessile serrated adenomas (SSAs) constitute a distinct class of
premalignant tumors in the intestine, which are characterized by a
saw-toothed and tufted tissue morphology, as well as by unique
transcriptional, mutational and epigenetic patterns.10–12 The most
prevalent mutation in human SSA is BRAFV600E, representing an
oncogenic alteration in the mitogen-activated protein kinase
(MAPK) cascade, which is composed of consecutively activated
rapidly accelerated ﬁbrosarcoma (RAF), mitogen/extracellular
1Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany; 2Department of Developmental Genetics, Max-Planck-
Institute for Molecular Genetics, Berlin, Germany; 3Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, München, Germany; 4German Cancer
Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany and 5Department of General Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin,
Berlin, Germany. Correspondence: Dr M Morkel, Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, CCM, Chariteplatz 1, Berlin
10117, Germany.
E-mail: markus.morkel@charite.de
Received 3 March 2014; revised 19 June 2014; accepted 24 June 2014
Oncogene (2014), 1–12
© 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14
www.nature.com/onc
signal-regulated kinase (MEK) and extracellular signal-regulated
kinase (ERK) kinases. In the normal intestine, MAPK activity mainly
relays pro-proliferative cues in the progenitor compartment of the
upper crypt.13 BRAF-activated serrated human tumors show
unique patterns of DNA methylation in CpG-rich regions10,14,15
and strong nuclear β-catenin staining, indicative of tumor-
associated activation of the Wnt/β-catenin pathway.16,17 Mice
with an oncogenic BRAFV637E knock-in mutation develop general-
ized serrated hyperplasia, thus corroborating an initiating role for
oncogenic BRAF in serrated adenoma.18 Aging BRAFV637E knock-in
mice exhibit focal tumor progression to dysplastic serrated
adenoma and metastatic carcinoma. Similar to the ﬁndings in
humans, more advanced stages of murine serrated tumors
showed intensiﬁed MAPK signaling and activating mutations in
the Wnt/β-catenin pathway. The speciﬁc epigenetic and muta-
tional patterns of serrated tumors of mice and humans suggest
that distinct evolutionary constraints exist in the progression of
intestinal tumors that are initiated by activating BRAF mutations.
Here, we analyze a novel mouse model carrying an inducible
transgene coding for human oncogenic BRAF. By analysis of
intestinal tissue in vivo and in primary organotypic culture, we
deﬁne effects of the main oncogenic driver pathways, MAPK and
of Wnt/β-catenin, on the intestinal cellular hierarchies. We could
show for the ﬁrst time that high levels of MAPK activity can result
in the loss of the affected tissue because such signals are not
compatible with the maintenance of ISC identity. We further
demonstrate that ISC loss induced by MAPK can be counteracted
by β-catenin activity, providing a rationale for the concomitant
activation of the BRAF/MAPK and β-catenin pathways during
serrated tumor progression.
RESULTS
Oncogenic BRAF activates MAPK signal transduction and modulates
cell fate-associated gene expression in colon cancer cells
We tested the effects of the two colon cancer-associated
mutations BRAFV600E and BRAFV600K 19 in Caco2-tet colon cancer
cells. To this end, we activated an inducible green ﬂuorescent
protein (GFP)-BRAFV600E or GFP-BRAFV600K in Caco2-tet cell by
addition of doxycycline to the medium. We found that induction
of either BRAF mutant induced the phosphorylation of the MAPK
signal transducers MEK1/2 and ERK1/2, and activated transcription
mediated by binding sites for the MAPK-associated transcription
factor ELK to a similar extent (Figures 1a and b). Both mutations
have previously been characterized as highly activating.20
Transcription mediated by FOXO3 or LEF/TCF, which are
associated with PI3K/AKT and Wnt/β-catenin signal transduction,
respectively,7,21 was not altered by either mutation.
We assessed expression of MAPK target genes by quantitative
reverse transcriptase PCR (qRT-PCR) and found that both
BRAFV600E and BRAFV600K activated Phlda1 and Dusp6, whereas
Spry2 was not BRAF-responsive in Caco2-tet cells (Figure 1c). Next,
we determined whether oncogenic BRAF modulates expression of
Birc5 and Axin2, which are highly active in stem cell-like colon
cancers, as well as Muc2 and Krt20, which are active in Goblet cell-
like colon cancers.2 We found that Birc5 and Axin2 were gradually
inhibited by increasing amounts of BRAFV600E or BRAFV600K,
whereas Muc2 and Krt20 were progressively activated (Figures
1d and e). These results suggest that activation of the BRAF/MAPK
signaling axis can affect cell fate-associated transcriptional activity
in colon cancer cells and thus may modulate cell differentiation
choices during intestinal tumor initiation and progression.
Transgenic expression of oncogenic BRAF induces intestinal
serration
To study the effects of oncogenic BRAF on cell hierarchies in the
intestinal epithelium, we engineered an inducible transgene for
the human oncogene BRAFV600K linked to the ﬂuorescent protein
tdTomato into a modiﬁed Gt(ROSA26)Sor locus22 of murine
embryonic stem cells and derived transgenic mice by diploid
aggregation (Figure 2a). In transgenic mice, BRAFV600K expression
in the intestine was induced by administration of doxycycline via
the drinking water. We were able to induce BRAFV600K in
transgenic mice for up to 4 days before they showed signs of
distress and had to be killed.
In the non-induced state, the small intestine of transgenic mice
displayed regular architecture and a smooth epithelial surface
with cylindrical enterocytes admixed with Goblet cells. Paneth
cells, as identiﬁed by eosinophilic cytoplasmic granules, were
restricted to the bases of the crypts. Signiﬁcant morphologic
alterations were found after 3 and 4 days of BRAFV600K induction
(Figure 2b, Supplementary Figure 1). The villus surface became
saw-toothed, and tufts of aggregated enterocytes were seen at
the villus tip. Basal positioning of nuclei in the epithelium was lost,
nuclei were enlarged and the nucleus to cytoplasm ratio was
increased. The contact surface of the cells to the basal membrane
often appeared to be narrowed, resulting in a hobnail appearance
of the cells and the presence of discohesive cell clusters. Paneth
cells lost their strict location at the base of the crypt and were also
found at more luminal positions. We frequently observed the
formation of rounded glands at crypt-to-villus junctions, which
contained Paneth cells. We also found that maturation of secretory
lineages was perturbed, and we frequently observed intermediary
cells that expressed both Goblet and Paneth cell markers
(Supplementary Figure 2).
In the large intestine changes were similar, yet less pronounced
(Figure 2b, Supplementary Figure 3). We observed generalized
Goblet cell-rich epithelial serration with widened luminal openings
of crypts. Similar to the surface alterations in the small bowel, tufts
of clustered cells projected into the lumen. Associated with the
widening of crypts and luminal openings, the submucosal space
between the epithelium and the muscularis appeared reduced to
only few visible ﬁbroblasts.
Transgenic expression of oncogenic BRAF induces MAPK
hyperactivation in the intestinal epithelium
We analyzed transgene expression and resulting changes in MAPK
cascade activity in the intestinal epithelium by western blots and
immunohistochemistry (IHC) (Figure 2c, Supplementary Figures 4
and 5). We detected low levels of endogenous RAF proteins in the
intestinal epithelium of non-induced mice, while transgenic
BRAFV600K contributed to a more pronounced RAF signal in
induced mice. In line, only low levels of the phosphorylated active
forms of MEK and ERK were present in non-induced mice, but
phosphorylation was stronger in induced animals. We compared
phospho-MEK1/2 and phospho-ERK1/2 levels in the intestinal
epithelium of induced mice with levels found in the human colon
cancer cell lines RKO and HT29, which both harbor a BRAFV600E
mutation. MEK1/2 and ERK1/2 showed activity levels of various
strengths in the intestinal epithelia of mice and in cell lines.
Phosphorylated ERK1/2 was most strongly elevated in RKO cells.
These western blot analyses demonstrate that transgenic
BRAFV600K induces MAPK activity in the intestine of mice to levels
comparable, but not exceeding those found in human colon
cancer cell lines.
Phospho-Mek1/2 and phospho-ERK1/2 signals were generalized
in all compartments spanning crypt bases to villus as assessed
by IHC (Supplementary Figures 4 and 5). However, the proliferative
zones were only slightly expanded after BRAFV600K induction
in both small and large intestine (Supplementary Figure 6).
We used qRT–PCR to quantify expression of well-known
MAPK target genes in the intestine and found strong induction
(Figure 2d), comparable to that seen in foci of dysplastic
progression in mice harboring a knock-in allele of oncogenic
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BRAFV637E.18 MAPK target genes were activated in both
crypts and villi of BRAFV600K-induced mice (Supplementary
Figure 7).
Transgenic expression of oncogenic BRAF causes loss of ISCs
We next analyzed the effects of ampliﬁed MAPK signal
transduction on the intestinal crypt, which contains ISCs and is
essential for tissue maintenance. In control mice, ISCs and
secretory Paneth cells were both restricted to the crypt base, as
assessed by RNA in situ hybridization for Olfm4 23 and Lysozyme
IHC, respectively (Figure 3a and Supplementary Figure 4).
Olfm4-positive ISCs had characteristic wedge-like shapes and
were mostly proliferative, as shown by Ki67 staining. In
striking contrast to non-induced controls, crypts of BRAFV600K-
induced mice displayed only very weak Olfm4 signals
already 3 days after induction, suggesting an exhaustive
loss of ISCs. Ki67-positive proliferative cells were frequently
found at the crypt base. However, these did not have the
characteristic shape of ISCs, but were round to cylindrical,
resembling proliferative cells of the TA zone. Furthermore,
Lysozyme-positive Paneth cells were displaced from the crypt
base and strongly positive in Periodic acid-Schiff (PAS) staining,
resembling Goblet cells and conﬁrming our previous analyses (see
Supplementary Figure 2 above).
To ascertain the loss of ISCs in crypts upon transgenic BRAFV600K
induction, we analyzed the expression of several ISC marker
genes23 by qRT–PCR and found all markers strongly reduced in
the induced intestines (Figure 3b).
To quantify the fraction of ISCs in normal versus BRAF-induced
crypts, we mated BRAFV600K transgenic and ﬁreﬂy luciferase/
tdTomato-transgenic control mice to Lgr5-EGFP stem cell-marking
reporter mice.24 Using ﬂuorescence-activated cell sorting (FACS),
we found that crypt cell suspensions isolated from control mice
contained between 3 and 8% of enhanced GFP (EGFP)-positive
stem cells, while crypt cell suspensions isolated from BRAFV600K
transgenic mice induced for 3 days contained o0.2% EGFP-
positive ISCs (Figure 3c).
Transgenic expression of oncogenic BRAF promotes TA cell
generation combined with ISC depletion
In order to elucidate the fate of ISCs upon BRAFV600K induction, we
ﬁrst evaluated end points of apoptotic and senescence programs,
Figure 1. Oncogenic BRAFV600E and BRAFV600K activate MAPK signal transduction, ELK activity and modulate cell fate-speciﬁc gene expression
in colon cancer cells. (a) Western blot analysis of non-induced and 24 h induced Caco2-tet BRAFV600E and BRAFV600K human colon cancer cells,
using antibodies directed against RAF, BRAF(V600E), MEK1, phospho-MEK1/2, ER1/2 phospho-ERK1/2 and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as a loading control. (b) Reporter assays in non-induced and 24h induced Caco2-tet BRAFV600E and BRAFV600K human
colon cancer cells, using luciferase reporters containing multimerized ELK, FOXO3 or LEF/TCF binding sites. (c–e) qRT–PCR analyses of gene
expression in induced Caco-tet GFP, GFP-BRAFV600E and GFP-BRAFV600K cells. Before analyses, cells were sorted according to transgene
expression. FACS plot in legend: windows 1–3 denote low, intermediate and high transgene-expressing populations. Inset 4 displays
untransfected Caco2-tet cells. (c) Analysis of MAPK target genes. (d) Analysis of marker genes for SC-like colon cancer. The intestinal SC marker
genes LGR5 and OLFM4 had too low expression to call in Caco2-tet cells. (e) Analysis of marker genes for Goblet-like colon cancer.
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which can be triggered as a response to BRAF.25,26 We found that
induction of BRAFV600K induced signiﬁcant DNA damage in the
intestine, as demonstrated by immunoﬂuorescence analysis of
phosphorylated histone γH2A. However, we did not ﬁnd increased
apoptosis in BRAFV600K-induced intestinal tissues, as assessed by
cleaved caspase 3 IHC (Supplementary Figure 8). Similarly,
oncogene-induced senescence was not observed, as indicated
by lack of staining for senescence-associated β-galactosidase
(Supplementary Figure 9).
We next analyzed gene expression in BRAFV600K-induced ISCs,
using tdTomato-BRAFV600K;Lgr5-EGFP or control tdTomato-luc;
Lgr5-EGFP compound transgenic mice. For this, we sorted cells
displaying both red and green ﬂuorescence, marking activity of
the BRAFV600K or control transgenes and the Lgr5-EGFP stem
cell-speciﬁc reporter, respectively. As almost no double-positive
cells were detected 2 or 3 days after BRAFV600K induction (see
Figure 3c and data not shown), we induced the BRAFV600K
transgene for only 24 h, and could isolate sufﬁcient numbers of
Figure 2. Transgenic BRAFV600K induces MAPK activity and serration in the intestinal epithelium. (a) Scheme of the transgene system used for
an inducible transgenic expression. For further details, see Vidigal et al.22 (b) Overview of tissue morphology after 4 days of transgenic
BRAFV600K induction, hematoxylin–eosin-stained parafﬁn sections are shown. For further detailed images, see Supplementary Figure 1.
(c) Western blot analysis of puriﬁed epithelium of non-induced and 3-day induced mice and human colon cancer cell lines carrying a
BRFAV600E mutation, using antibodies directed against RAF, MEK1, phospho-MEK1/2, ER1/2 phospho-ERK1/2 and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as a loading control. (d) Expression of the MAPK target genes Phlda1, Phlda2, Dusp6, Spry2 and Fos in intestines of
non-induced, 3- and 4-day induced mice, as assessed by qRT–PCR.
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double-ﬂuorescent cells by FACS, along with single-ﬂuorescent
and non-ﬂuorescent cell populations. Expression proﬁles of sorted
cells were analyzed by microarrays. As expected, MAPK target
genes such Areg, Ier3 and Tnfrsf12a, as well as the MAPK targets
and feedback inhibitors Dusp4, Dusp6, Spry2 and Spry4 were
strongly activated in ISCs following BRAFV600K induction
(Figure 4a). We also identiﬁed many novel BRAF target genes in
the intestine, prominently among these the putative signal
transducer gene Anxa10, which has recently been identiﬁed as a
speciﬁc marker for SSA in human patients27 (Figures 4b and c).
We used gene set enrichment analysis28 to analyze activities of
gene expression programs in the sorted ISCs (Figure 4d). We
evaluated gene signatures comprising MAPK or β-catenin target
genes, as well as signature genes enriched in stem cells or
proliferative committed TA cells of the intestinal epithelium.29–32
As expected, we found that a signature of MAPK target genes was
strongly induced by BRAFV600K in ISCs when compared with
luciferase-expressing control ISCs. However, signatures of
β-catenin target genes were not signiﬁcantly changed. Strikingly,
we found a strongly activated signature of proliferative TA cells in
the BRAFV600K-induced sorted Lgr5-EGFP-positive cells, while the
ISC signature was not signiﬁcantly altered at this early time point
after transgene induction (Figure 4d and Supplementary
Figure 10). Taken together, these ﬁndings show that ISC and TA
cell gene expression programs are both active side by side in the
BRAFV600K-expressing ISCs 24 h after induction, and the latter is
strongly enhanced. Our gene expression data thus conﬁrm and
extend the morphological analyses, and suggest that ISCs rapidly
and collectively convert to committed TA progenitors after
BRAFV600K induction. Furthermore, secretory lineages are per-
turbed and intermediate secretory cells emerge (for a model of
the resulting crypt cell types, see Figure 4e).
Effects of oncogenic BRAF in organotypic culture can be rescued
by MEK inhibition
To follow tissue development and signal transduction in the
intestinal epithelium after BRAFV600K induction in more detail, we
took advantage of organotypic primary tissue culture.33 We were
unable to establish organoids from intestines of mice induced for
BRAFV600K expression for 3 or 4 days, further supporting our
ﬁnding that ISCs are lost by the treatment. Organoids prepared
from non-induced BRAFV600K transgenic mice that were main-
tained without doxycycline were organized into radial crypts and a
central differentiated villus domain containing debris of extruded
cells, as expected. Upon BRAFV600K induction, organoids under-
went rapid changes: crypts became progressively wider and
shallower, until they were indistinguishable from the central villus
tissue (Figure 5a). Time-lapse photography revealed rapid devel-
opment of an irregular and highly motile apical epithelial surface
and frequent loss of Paneth cell localization (data not shown).
Sections of induced organoids frequently displayed serration,
reminiscent of the morphological changes observed in vivo
(Supplementary Figure 11). These induced organoids showed a
markedly reduced expression of crypt domain markers, such as for
the stem cell markers Lgr5, Olfm4 and Cd44, the Paneth cell marker
Mmp7, the Wnt target gene Axin2 and for the Goblet cell marker
Muc2. In contrast, expression of the villus enterocyte marker Fabp2
was not signiﬁcantly altered (Figure 5b). Within 1–2 days of
induction, organoids lost all structure and disintegrated. These
data are in agreement with the in vivo analyses, and validate that
following BRAFV600K induction epithelial serration is induced and
ISCs are lost in a tissue-intrinsic manner. In addition, we also
observed loss of the proliferative compartment, which probably
can no longer be maintained in the absence of stem cells and after
Figure 3. Transgenic BRAFV600K induces loss of ISCs. (a) Visualization of ISCs (Olfm4 RNA in situ hybridization), proliferative cells (Ki67 IHC),
Paneth cells (Lysozyme IHC) and Goblet cells (Periodic acid-Schiff staining) in crypts of non-induced and BRAFV600E-induced mice. (b)
Expression of ISC marker genes Lgr5, Olfm4, Prom1/Cd133, Ascl2 and Bmi1 23 in intestines of non-induced, 3- and 4-day induced mice, as
assessed by qRT–PCR. (c) FACS analysis of crypt cell suspensions isolated from induced compound transgenic mice carrying an Lgr5-EGFP
stem cell reporter gene24 and an inducible tdTomato/BRAFV600E or tdTomato/ﬁreﬂy (FLUC) luciferase control transgene.
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Figure 4. Transgenic BRAFV600K induces MAPK activity and TA cell-speciﬁc gene expression programs in ISCs. (a) Gene expression in sorted
crypt cell populations of BRAFV600K-induced and luciferase-induced control mice. Expression of MAPK target genes is shown (MAPK targets
selected from Rad et al.18). Color code is red for high relative expression, blue for low relative expression. Mouse transgenes and cell
populations are indicated on top of ﬁgure. ‘SC GFP+’ indicates (stem cell) populations positive for green ﬂuorescence of the Lgr5-EGFP
reporter, ‘CRYPT’ indicates populations negative for green ﬂuorescence, ‘tdT+’ indicates populations that were sorted for ﬂuorescence of the
tdTomato (linked to BRAFV600E or ﬁreﬂy luciferase) transgene. (b) Expression of genes strongly induced by transgenic BRAFV600E. Color code is
as in a. (c) Expression of Anxa10, a speciﬁc marker gene of SSA, as assessed by qRT–PCR, 3 and 4 days after BRAFV600E induction in the intestine.
(d) Gene set enrichment analysis (GSEA) analysis of stem cell populations isolated from BRAFV600E-induced versus ﬁreﬂy luciferase control
transgenic mice. Gene signatures of MAPK target genes,29 TA cell-enriched genes32 and β-catenin target genes31 are shown. Analysis of further
β-catenin target genes30 and a stem cell-speciﬁc signature32 can be found in the Supplementary Figure 10. Enrichment score graphs (top,
green), signature gene distributions (black lines below ES curves), P-values and false discovery rates (FDRs) are given. Signiﬁcance cutoffs were
Po0.05, FDR o0.25. (e) Schematic representation of cell types in the crypts before and after BRAFV600K induction.
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loss of crypt topology. The enhanced disintegration of the tissue
architecture in vitro can likely be attributed to the lack of
supporting effects from the surrounding tissues, which are an
important source for growth factors in vivo but are lacking in
organotypic culture.34
In order to dissect signaling cascades downstream of oncogenic
BRAF, we treated organotypic cultures with small-molecule
inhibitors. In a series of proof-of-principle experiments, we ﬁrst
assessed the effects of PLX4720,35 a speciﬁc inhibitor of BRAFV600E
and possibly other oncogenic forms of BRAF. In non-induced
organotypic cultures, PLX4720 did not cause any effects. When
BRAFV600K was induced using a low concentration of doxycycline,
PLX4720-treated cultures preserved crypt/villus topology and
survived for several days, indicating inhibition of BRAFV600K by
PLX4720 (Figures 5c and d). Under these conditions, PLX4720 also
suppressed the strong activation of the MAPK target genes Fos
and Dusp6 that were induced by BRAFV600K (Supplementary Figure
12). To establish whether increased MAPK activity is causative for
the loss of ISCs and crypts, we inhibited the downstream MEK1/2
kinases using AZD624436 and alternatively the phosphatidylino-
sitol 3 kinase cascade using the speciﬁc inhibitor GDC0941.37
Signiﬁcantly, MEK inhibition by AZD6244 had a similar protective
effect as PLX4720 and supported organoid survival in the
presence of doxycycline (Figure 5d). In contrast, inhibition of the
phosphatidylinositol 3 kinase cascade by GDC0941 did not rescue
organoid survival. These results indicate that oncogenic signals
causing serration and loss of ISCs are transduced via activation of
the MAPK cascade.
Activation of Wnt/β-catenin signaling rescues ISC loss after
induction of oncogenic BRAF
In our mouse model, induction of transgenic BRAFV600K resulted in
strong MAPK signal activation and in epithelial serration, yet also
in loss of ISCs. As the ISC compartment is maintained by Wnt and
Notch signals,1 we tested the effects of the ligands Wnt3a and
Jagged1, which are known to activate the Wnt and Notch
pathways in organotypic culture.33 We found that Wnt3a, but not
Figure 5. Transgenic BRAFV600K results in a MAPK-dependent loss of crypt domains in organotypic culture. (a) Stills from time-lapse
microscopy of BRAFV600K-induced organoids. Time span since induction is given in panels. Yellow overlay indicates ﬂuorescence of the
tdTomato-2A-BRAFV600K transgene. (b) qRT–PCR analysis of marker gene expression in non-induced versus BRAFV600K-induced organoids, 24 h
after induction with 2 μg/ml doxycycline. (c, d) The BRAFV600E inhibitor PLX4720 and the MEK1/2 inhibitor AZD6244 rescue organoids from
deleterious effects of transgenic BRAFV600K. (c) Microscopic images of organotypic cultures, 24 h after addition of doxycycline and/or PLX4720,
as indicated. Green dots mark intact organoids, red dots mark disintegrated organoids. (d) Quantiﬁcation of organoid survival 36 h after
BRFAV600K transgene induction with doxycycline in the presence or absence of small-molecule inhibitors. DMSO: solvent control; PLX; PLX4720
(42 μM); AZD: AZD6244 (8 μM); GDC: GDC0941 500 nM). n⩾ 4 wells in multiple experiments, signiﬁcance calculated by Student’s t-test.
*Po0.005, else NS (not signiﬁcant).
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Jagged1, led to a partial rescue of organoid integrity (Figure 6a).
Furthermore, we used the selective GSK3β-inhibitor CHIR99021,38
which stabilizes β-catenin.39 In organotypic culture, CHIR99021
was tolerated and resulted in a visible expansion of crypt domains
after 2 days, probably due to the induction of ectopic β-catenin
activity that is normally restricted to the crypt base (Figure 6b).
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Remarkably, when we induced BRAFV600K in cultures, inhibition of
GSK3β by CHIR99021 resulted in a substantial rescue of crypt-villus
architecture and in organoid survival (Figures 6a and b). We
observed that even when BRAFV600K was strongly induced by high
levels of doxycycline, GSK3β inhibition resulted in the survival of
many organoids. Their crypt domains persisted while becoming
enlarged and hyperplastic. In agreement with the changes in
organoid architecture observed, we found that CHIR99021
strongly activated the ISC marker genes Lgr5 and Olfm4, and that
this activation was strong even in the presence of induced
BRAFV600K (Figure 6c).
We have previously shown that transgenic expression of
stabilized β-catenin promotes stem cell identity in intestinal
epithelium.9 We therefore asked whether activation of β-catenin
signaling could rescue the stem cells loss caused by transgenic
BRAFV600K in vivo. To this end, we engineered a triple transgene
into an inducible Gt(ROSA26)Sor locus, consisting of tdTomato,
BRAFV600K and stabilized β-catenin. We found that BRAFV600K/
β-cateninstab compound transgenic mice also develop serration.
Importantly, and in contrast to the BRAFV600K mice analyzed
before, we observed the presence of many residual Olfm4-positive
ISCs 3 days after transgene induction (Figure 6d). Taken together,
our experiments demonstrate that enhanced Wnt/β-catenin
pathway activity can strongly reduce the loss of ISCs in vitro and
in vivo, caused by BRAFV600K-induced MAPK hyperactivation.
Finally, we analyzed ISCs in a murine tumor progression model,
based on knock-in of a BRAFV600E homolog18 (Figure 6e and
Supplementary Figure 13). These mice display serrated intestinal
hyperplasia upon oncogenic activation of BRAF, and develop
progressive dysplastic foci that frequently contain activating
mutations in the Wnt/β-catenin pathway in addition to the
initiating oncogenic BRAF. When visualizing ISCs by Olfm4 in situ
hybridization, we found that BRAF-activated hyperplastic intes-
tines showed diffuse and scattered signals in neighboring crypts,
whereas intestines of control mice displayed a continuous band of
Olfm4-positive crypts. We also observed a strong reduction of
mature Paneth cells, as assessed by Lysozyme IHC. We next used
qRT–PCR to assess expression levels of the ISC markers Lgr5 and
Ascl2 during the different stages of tumor progression in
BRAFV637E mice (Figure 6f). We found that hyperplastic intestines
showed a marked reduction of expression for both Lgr5 and Ascl2
relative to non-recombined control intestines. In contrast,
progressive dysplastic foci that frequently contain Wnt/β-catenin
mutations displayed an increase in ISC marker expression. These
data support and extend our previous results, suggesting that an
initiating BRAF mutation can reduce the ISC pool, whereas
enhanced Wnt/β-catenin signals expand the ISC pool at later
stages of serrated intestinal tumor progression.
DISCUSSION
We report a novel oncogene mouse model that is based on
conditional activation of transgenic BRAFV600K. Induced mice
showed generalized serration of the intestinal epithelium,
combined with strong reduction of the ISC pool.
Transgenic induction of oncogenic BRAF rapidly induced
a phenotype that displayed striking parallels to SSA in the
human colon. In particular, the mouse model showed a serrated
epithelial morphology, tufting of cells at the luminal borders,
reduction of the interluminal mesenchymal tissue and widening of
the colonic crypts,40 which are all features of human SSA. We
therefore conclude that activation of MAPK signaling by
oncogenic BRAF is sufﬁcient to induce multiple pathognomonic
features of SSA. We furthermore noticed a high extent of cellular
atypia (that is, a high nucleus-to-cytoplasmic ratio) normally
associated with later stages of serrated tumor progression in
humans.
Transgenic expression of BRAFV600K in the intestinal epithelium
converted stem cells collectively into proliferative TA cells.
The resulting ISC depletion was counteracted by upregulation of
Wnt/β-catenin signaling by Wnt3a ligand or by small-molecule
inhibition of GSK3β in organotypic culture, or by transgenic
expression of stabilized β-catenin in the mouse intestine. Both
high MAPK and β-catenin activity has been
noted in human SSA16,17 and in BRAF-driven serrated intestinal
tumors in the mouse.18 Our data suggest that the concomitant
activation of MAPK and β-catenin could be required to assure
stem cell and consequently tumor tissue maintenance during
progression of SSA, and our ISC marker analysis during serrated
tumor progression in the mouse is in agreement with such
a model.
The transgenic mouse model presented here expresses
BRAFV600K to an extent that exceeds endogenous BRAF trans-
cript or protein levels in normal intestinal cells (for quantiﬁcation
of transgene expression, see Figure 2c and Supplementary
Figure 14). This is in contrast to previous mouse models of
oncogenic activation of BRAF, which used knock-in alleles.18,26 As
a consequence, BRAFV600K induction in our mouse model results in
immediate and strong activation the MAPK cascade. Conse-
quently, MAPK target genes in transgenic BRAFV600K mice were
induced to levels characteristic of more advanced stages of tumor
progression obtained in BRAFV637E knock-in mice.18 Mechanisms
of how MAPK signals are further intensiﬁed in serrated intestinal
tumors of mice and humans after the initial BRAF mutation remain
to be further deﬁned. It is of note that ampliﬁcation of oncogenic
BRAF has been found in colon cancer cell lines that were resistant
to MEK inhibition41 and also in BRAF-mutant human colorectal
cancer,42 demonstrating that high levels of oncogenic BRAF are
tolerated in more advanced tumor stages.
Figure 6. β-Catenin activity antagonizes loss of ISCs induced by oncogenic BRAF. (a, b) Quantiﬁcation of survival of BRAFV600K transgenic
organotypic cultures, after induction with 250 ng/ml, 500 ng/ml or 2 μg/ml of doxycycline and the following growth factors and inhibitors:
Jagged1 peptide (1 μM), Wnt3a peptide (100 ng/ml), CHIR99021 (6 μM), PLX4720 (42 μM). (a) Quantiﬁcation of organoid survival in n⩾ 4 wells in
multiple experiments, signiﬁcance calculated by Student’s t-test. *Po0.005, else NS (not signiﬁcant). (b) Images of representative organoids
36 h after DOX and/or inhibitor supplementation, as indicated. (c) Expression of the stem cell marker genes Olfm4 and Lgr5, and of the villus
enterocyte marker gene Fabp2 in organoid cultures, 24 h after induction with 500 ng/ml doxycycline, and/or treatment with 42 μM PLX4720 or
6 μM CHIR99021, as indicated. (d) Partial rescue of Olfm4-positive ISCs in vivo by transgenic stabilized β-catenin 3 days after transgene
induction. Hematoxylin and eosin (HE) stainings (top panels), IHC for tdTomato (transgene induction, middle panels) and Olfm4 RNA in situ
hybridization (ISC visualization, lower panels) are given. Red arrows point to crypt bases, insert shows magniﬁcation of representative crypts
(lower panels). Compositions of transgenes are given above. (e, f) Analysis of ISCs in a mouse model of serrated tumor progression, initiated
by BRAFV637E.18 (e) Visualization of ISCs by Olfm4 RNA in situ hybridization in control and BRAFV637E hyperplastic intestines. Red line indicates
crypt level. Inserts show magniﬁcation of individual crypts. It is of note that crypts of BRAFV637E are often strongly variegated. For further
images, see Supplementary Figure 13. (f) Expression of ISC marker genes Lgr5 and Ascl223 in normal (N) and serrated hyperplastic (SH)
intestines, as well as in low-grade (LGD) and high-grade (HGD) dysplastic progressive foci, as assessed by qRT–PCR. Arrows below indicate the
progression model,18 with BRAFV637E inducing sustained hyperplasia and Wnt/β-catenin mutations leading to dysplastic progression.
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Oncogenic forms of KRAS and BRAF are mutually exclusive
drivers of oncogenic progression in human colon cancer.
Although both oncogenes activate the MAPK cascade, differences
also exist: ﬁrst, KRAS activates a number of further signal
transducers in addition to BRAF,43 and second, oncogenic
KRAS, but not BRAF, is subject to strong additional feedback
control within the MAPK cascade.44 These differences may
explain why BRAF-mutated tumors have distinct molecular
features and therapeutic proﬁles compared with BRAF
non-mutated tumors, including those that are KRAS mutated.3
Similar to BRAF, oncogenic KRAS can also initiate serrated
lesions in the mouse,45 but in contrast to BRAF, tumor progression
in KRAS-transgenic mice crucially depends on loss of the
tumor-suppressor Ink4a/ARF, but not on Wnt/β-catenin activation.
The KRAS and BRAF oncogenes may also have contrasting
effects on cellular hierarchies in the intestine, as oncogenic
KRAS in combination with loss of APC can induce ectopic stem
cells in the mouse intestine,46 and KRAS mutations produced cells
that favor ISC over TA cell fate and thus spread within individual
crypts.47 In contrast, our results suggest that oncogenic activation
of BRAF would support the adoption of TA over ISC cell fate, which
would result in preferential exclusion from the stem cell pool and
clonal elimination. However, this assumption has not been tested
on a clonal basis here.
Wnt and MAPK signaling have been shown to co-operate
during conventional intestinal tumor progression, with
APC/β-catenin pathway mutations occurring ﬁrst: nuclear
localization of β-catenin and expression of cancer stem cell
markers after loss of APC are increased by mutational activation of
the MAPK-controlling GTPase KRAS,48,49 and in turn KRAS can be
stabilized by β-catenin activity.50 In contrast, activation of MAPK
signaling downstream of oncogenic BRAF can inhibit β-catenin
effects in melanoma.51 Therefore, interactions between the two
signaling cascades may be highly cell type- and context-speciﬁc.52
To assess whether BRAF/MAPK activation may immediately alter
transcription of β-catenin target genes during serrated tumor
development, we analyzed FAC-sorted residual ISCs after short-
term induction of BRAFV600K by microarrays, but found no
immediate changes in β-catenin target gene expression. A
molecular mechanism connecting the BRAF-hyperactivated MAPK
and the physiological β-catenin pathway in the intestine may
therefore depend partly on competing downstream transcrip-
tional programs promoting progenitor TA versus ISC cellular
states, respectively.
Although the intestinal epithelium is highly proliferative and
has a rapid turnover, intestinal tumor progression is a long-term
process. This suggests the existence of strong protective
mechanisms limiting survival of cells that acquired oncogenic
mutations in order to prohibit tumor initiation or progression.
Mutational activation of BRAF elicits oncogene-induced senes-
cence and apoptosis in melanoma.25,53,54 However, in agreement
with another recent publication,18 we observed neither senes-
cence nor apoptosis-related cleaved caspase3 in the intestine after
oncogenic BRAF induction, although it has been reported before
under similar conditions.26 Strikingly, our data suggest the
existence of a novel alternative fail-safe mechanism that may
block tumor development after mutational activation of BRAF, that
is, by oncogene-induced loss of stem cells. This mechanism could
represent the prototype of a more general paradigm, as oncogene
activities could possibly result in cellular signaling states
incompatible with the maintenance of stem cell identity in other
tissues, too, leading to discontinuation of the mutated cell
progeny and clonal elimination. Further studies of oncogene-
induced loss of stem cells could thus lead to new strategies to
exploit colon cancer vulnerabilities.
MATERIALS AND METHODS
Mice
Transgene cassettes were constructed by linking tdTomato to human
BRAFV600K and/or murine stabilized mutant Ctnnb1 (S33A, S37A, T41A and
S45A) and/or ﬁreﬂy luciferase via 2A peptides, and subsequent cloning of
these gene combinations into a doxycycline-inducible expression cassette
ﬂanked by wild-type and mutant loxP sites. Transgenes were integrated
into the previously modiﬁed Gt(ROSA)26Sor locus of F1 hybrid B6/129S6
embryonic stem cells by Cre recombinase-mediated cassette exchange.
Recombined embryonic stem cell clones were identiﬁed by Southern
blotting, as described previously.22 Animals were generated by diploid
aggregation. Previous experiments in adult mice have shown that this
conﬁguration results in high transgene induction in the intestinal
epithelium, lower induction in some other tissues including skin and no
discernible transgene expression in most tissues tested (data not shown).
Mice were housed at a 12 h/12 h light/dark cycle and fed ad libitum. First-
and second-generation transgenic mice with apparent 100% transgenic
contribution were used for experiments (at least n= 4 mice per genotype
and time point). Transgenes were induced by administration of
doxycycline (4 mg/ml) provided in a 1% sucrose solution via the drinking
water. Primer sequences for genotyping are given in Supplementary
Table 1. Termination criteria for the animal experiments were either weight
loss or apparent distress, as indicated by a reduction of foraging activity or
shivering. Animal experimentation was approved by Berlin authorities
LAGeSo (G0185/09).
Organotypic culture
Organoid cultures were initiated and propagated as described in reference
Sato et al.,33 in 24-well or 48-well plates, using 15 or 30 μl of Matrigel (BD,
Heidelberg, Germany) per well. Crypt culture media were exchanged every
other day, and cultures were passaged every 5–7 days. For all small-
molecule inhibitors, maximal tolerated concentrations were determined in
organoid culture in the absence of transgenic induction. The following
inducers and small-molecule inhibitors were used: doxycycline (250 ng/ml,
500 ng/ml and 2 μg/ml for weak, intermediary and strong transgene
induction, respectively), PLX4720 (42 μM), AZD6244 (8 μM), GDC0941
(500 nM), CHIR99021 (6 μM). Jagged1 (AnaSpec, Seraing, Belgium) and
Wnt3a (Cell Signaling, Danvers, MA, USA) peptides were used at 1 μM and
100 ng/ml, respectively. For signal inhibition experiments, doxycycline and
small-molecule inhibitors were added at the same time, and wells were
photographed 24, 36, 48 and 72 h after induction. Organoid survival
was quantiﬁed from photographs, from at least three independent
experiments.
Cell culture
Caco2-tet cells were tested to have no mutations in BRAF, KRAS, NRAS and
MAP2K1 (own unpublished data). Cells were maintained in Dulbecco's
modiﬁed Eagle's medium containing 10% fetal calf serum. Caco2-tet cells
have previously been modiﬁed to express a second-generation tetra-
cycline-regulated transactivator and transcriptional silencer.44,55 Caco2-tet
were transfected using Lipofectamine 2000 (Life Technologies, Darmstadt,
Germany) as per the manufacturer’s instructions, using tetracycline-
inducible plasmids coding for GFP, or combinations of GFP with BRAFV600E
or BRAFV600K. We used luciferase reporter constructs with multimerized
ELK, FOXO3 or LEF/TCF sites. Generally, 6 h after transfection, medium was
exchanged to Dulbecco’s modiﬁed Eagle’s medium, 0.2% fetal calf serum
and 2 μg/ml doxycycline for induction. Cells were harvested 24–36 h after
transfection. Reporter activity was measured using a dual-luciferase-assay
(Life Technologies). FACS sorting of Caco2 cells for GFP expression was
done using an Aria II sorter (BD).
IHC, RNA in situ hybridization, western analysis
For IHC and in situ hybridization, tissues were ﬁxed in 4% formaldehyde,
dehydrated via a graded ethanol series, embedded in parafﬁn and
sectioned at 4 μm. The following antibodies were used for IHC: anti-KI67
(1:200; #ab16667 Abcam, Cambridge, UK), anti-RFP (1:200; #600-401-379
Rockland, Gilbertsville, PA, USA), anti-Lysozyme (1:200; #18-0039 Life
Technologies), anti-ITF (1:100; Santa Cruz, Dallas, TX, USA), anti-phospho-
MEK1/2 (1:100; #9121 Cell Signaling), anti-phospho-ERK1/2 (1:200; #9101
Cell Signaling). ImmPRESS secondary antibody and NovaRED substrate kits
(Vector Labs, Burlingame, CA, USA) were used for IHC. Olfm4 in situ
hybridization was carried out using standard protocols. Primer sequences
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ﬂanking the in situ probe are listed in Supplementary Table 1. DNA damage
was detected by staining for γH2AX, using the HCS DNA damage kit (Life
Technologies), following the manufacturer’s instructions. For SA-β-galac-
tosidase staining, fresh tissues of induced and control mice were
embedded in Tissue TEK (Sakura, Alphen, The Netherlands),
snap-frozen and sectioned at 20 μM on a cryostat. Sections were stained
using the Senescence β-Galactosidase Kit (Cell Signaling), following the
manufacturer’s instructions.
For western analysis, puriﬁed intestinal epithelium or cell lines were
lysed in sodium dodecyl sulfate lysis buffer and protein content
was quantiﬁed by a BCA assay (Thermo Fisher, Waltham, MA, USA).
Twenty or 40 μg of protein lysates was separated on 12% polyacrylamide
gels, and blotted onto nitrocellulose membranes. The following
antibodies were used: anti-phospho-MEK1/2 (1:500; #9121 Cell Signaling),
anti-phospho-ERK1/2 (1:500; #9101 Cell Signaling), anti-MEK1 (1:500;
#9122 Cell Signaling), anti-ERK1/2 (1:500; #9102 Cell Signaling), RAF
(1:200; #55522 Santa Cruz), anti-BRAF(V600E) (1:400; Spring Bioscience,
Pleasanton, CA, USA), glyceraldehyde 3-phosphate dehydrogenase (1:10
000; #AM4300 Life Technologies). Alexa ﬂuorophore-coupled secondary
antibodies and an Odyssey scanner (Li-Cor, Bad Homburg, Germany) were
used for visualization.
qRT–PCR and microarray analysis
For RNA analysis, villi were scraped from the inner intestinal surface after
initial washing steps, whereas crypts were isolated by ﬁltering (70 μm, BD)
after phosphate-buffered saline/EDTA treatment, as described in Sato
et al.33 For total tissue analysis, small pieces of the intestine were
homogenized in Trizol (Life Technologies) using a Tissue Lyser machine
(Qiagen, Hilden, Germany). Single-cell suspensions for FACS were prepared
by digesting crypts of compound transgenic mice in 500 μg/ml trypsin and
0.8 μ/ml DNAseI for approximately 20min at room temperature. Cells were
microscopically examined for proper dissociation, washed and resus-
pended in Suspension Minimal Essential Medium (SMEM) (Life Technolo-
gies) containing DNAseI and subsequently ﬁltered (30 μM; Celltrics ﬁlter
Partec, Münster, Germany). For FACS, an Aria SORP (BD) was used. For each
proﬁle, between 2000 and 20 000 cells were sorted directly into Qiagen
buffer RLT containing 1% β-mercaptoethanol.
Total RNA was isolated from tissue and cell samples using RNeasy
kits (Qiagen). Complementary DNA was synthesized from total RNA using
the Transcriptor High Fidelity cDNA synthesis kit (Roche, Penzberg,
Germany) as per the manufacturer’s instructions. qRT–PCR was carried
out using SYBR green (Promega, Mannheim, Germany) standard protocols.
Relative expression was calculated using the ΔΔCt method and GAPDH
(human) or Pmm2 (mouse) gene expression for normalization. qRT–PCR
primer sequences are provided in Supplementary Table 1. Lgr5 and Ascl2
gene expression in BRAFV637E mice was determined by Taqman qRT-PCR
(Qiagen), as described in Rad et al.18 Gene expression proﬁling from FACS-
sorted cell populations was done at AROS Applied Biotechnology (Aarhus,
Denmark) using Illumina MouseRef-8 v2 chips and the NuGEN procedure
for probe labeling. Expression data were calculated and normalized in
Genome Studio GX 1.9 (Illumina, San Diego, CA, USA), using quantile
normalization. Gene expression data were visualized using MultiExperi-
ment Viewer (http://www.tm4.org). Gene set enrichment analysis was
performed using pre-normalized Illumina gene expression data, following
the authors guidelines.28 Gene signatures and associated references are
listed in Supplementary Table 2. Gene expression data are available in GEO
under GSE50678.
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